The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.
 
Jung-Yun Lee
Honoraria - AstraZeneca; Genmab; Merck Serono; MSD; Regeneron; Seagen
Consulting or Advisory Role - Abbvie (Inst); Advenchen Laboratories (Inst); Alkermes (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); BerGenBio (Inst); bms (Inst); CanariaBio (Inst); Cellid (Inst); CKD pharm (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); genemedicine (Inst); Genmab (Inst); GI Innovation (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Janssen Oncology (Inst); Kelun (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD; Novartis (Inst); onconic therapeutics (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Sutro Biopharma (Inst); Synthon (Inst); Takeda (Inst); Torl Biotherapeutics (Inst); Zymeworks (Inst)
Speakers' Bureau - AstraZeneca; Eisai; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Carolina Ibanez
Consulting or Advisory Role - GlaxoSmithKline; MSD; Novartis; Pfizer
Research Funding - BMS; MSD; Pfizer
Travel, Accommodations, Expenses - MSD
 
Mariusz Bidzinski
No Relationships to Disclose
 
Ora Rosengarten
No Relationships to Disclose
 
Emad Matanes
No Relationships to Disclose
 
Victoria Mandilaras
Honoraria - Abbvie; AstraZeneca; GlaxoSmithKline; Merck
Consulting or Advisory Role - Abbvie; AstraZeneca; GlaxoSmithKline
Travel, Accommodations, Expenses - Abbvie; GlaxoSmithKline; Karyopharm Therapeutics
 
Toon Van Gorp
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Speakers' Bureau - Abbvie (Inst); AstraZeneca (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Marta Gil-Martin
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Eisai; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; MSD Oncology
 
Francesco Raspagliesi
Honoraria - GlaxoSmithKline; MSD Oncology
Consulting or Advisory Role - AstraZeneca/Merck (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Chien-Hsing Lu
Stock and Other Ownership Interests - Moderna Therapeutics
 
Eduardo Yanez
No Relationships to Disclose
 
Ronnie Shapira-Frommer
Honoraria - Sanofi,Medison pharma, BMS, MSD, Neopharm
Consulting or Advisory Role - MSD, Astra-Zeneca, Novartis
Research Funding - MSD
 
Christof Vulsteke
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Atheneum; Bayer; Bristol-Myers Squibb/Pfizer; GlaxoSmithKline; ipsen; Janssen; LEO Pharma; MSD; Pfizer; Roche/Genentech
Research Funding - LEO Pharma (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Roche
 
Alejandro Acevedo
No Relationships to Disclose
 
Eugenia Girda
Consulting or Advisory Role - Merck
 
Ana Oaknin
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OncoXerna Therapeutics; PharmaMar; Regeneron; Roche; Seagen / Pfizer; Shattuck Labs; Sutro Biopharma; TORL Therapuetics; Zentalis; Zymeworks
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Immunogen; MSD; Roche
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Steven Townson
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yiwei Zhang
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Julie Kobie
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Domenica Lorusso
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo/Lilly; Genmab; GlaxoSmithKline; Immunogen; MSD; Novartis; Novocure; Oncoinvest; PharmaMar; Seagen; Sutro Biopharma
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; ImmunoGen; MSD; Seagen
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Pharma& (Inst); PharmaMar (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Menarini
(OPTIONAL) Uncompensated Relationships - ENGOT; Gynecological Cancer InterGroup; MITO